Researchers from the Research Center Nutrition from the University of Navarra They are looking for volunteers with type 2 diabetes, aged 18 to 70, to participate in the DiabeT2Predict project, an innovative initiative aimed at improving control of this disease.
The combination of advances in the analysis of intestinal microbiota and genetic tools will make it possible to apply a precision nutritional approach for better control of type 2 diabetes based on the genetic profile and modulation of the microbiota of participants.
Volunteers will receive specialized care and exhaustive clinical monitoring, in order to personalize interventions and improve glycemic control based on the individual characteristics of each patient. To participate in the study, you must write an email to [email protected] or call 948 425 744.
“Our goal is to apply personalized nutrition thanks to supplementation with probiotics and postbiotics to address glycemic control, better understand the particularities of each patient and adapt treatment according to their genetics and intestinal microbiota,” explains Pedro González Muniesa, principal investigator of the study at the University of Navarra.
“This approach will allow us to offer nutritional solutions based on supplementation with microbiota modulators as a new, more effective and drug-compatible strategy that helps reduce the health impact of type 2 diabetes in Spain, which currently represents 9% of total health spending.
The project is carried out by a consortium of research entities and biotechnology companies. Led by Genbioma in collaboration with Patia, the Biobizkaia Health Research Institute and several teams from the University of Navarra (the Clínica Universidad de Navarra, CRO, CIMA LAB Diagnostics and the Nutrition Research Center), the study is funded by 1.7 million euros from the Ministry of Science and Innovation and is also funded by the European Union.
An innovative and safe strategy for the control of type 2 diabetes
As part of the study, the effectiveness of a probiotic/postbiotic formula developed by Genbioma, which aims to regulate blood sugar levels by modulating the intestinal microbiota, will be evaluated. In addition, thanks to an advanced genetic prediction tool, developed by Patia, researchers will be able to adapt recommendations to the physiology of each patient, allowing more conscious and personalized decision-making in the management of their health.
Type 2 diabetes constitutes a global pandemic and Spain is currently the second European country with the highest incidence rate of this disease, with almost 400,000 new diagnoses per year among adults. “The novelty of this study is that we do not intend to replace pharmacological treatment, but rather provide each patient with all the information they need to modify their lifestyle and eating habits, so that postbiotic supplementation is the as efficient as possible,” he said. explains González Muniesa.
Additionally, since it is a nutritional intervention with postbiotics as safe nutritional supplements that have been previously tested with diabetes medications, the transfer of research from the laboratory to patients is much more direct and no side effects or interaction with medications is expected. it’s safer.
